PD-1 (delivery anchor) / IL-2 receptor (effector)

Class

Fusion protein (bifunctional alpha-PD-1/IL-2 immunocytokine)

Pathway

PD-1 immune checkpoint engagement combined with localized IL-2 receptor signaling

PD-1 is a receptor found on the surface of activated T cells, the immune cells responsible for recognizing and destroying abnormal or infected cells. When PD-1 is engaged by its natural partner molecules, it sends an inhibitory signal that dampens T-cell activity, a mechanism tumors often exploit to escape immune attack. Blocking PD-1 is an established way to restore antitumor immune responses. Interleukin-2 (IL-2) is a separate signaling protein that drives T cells and natural killer cells to multiply and become more effective at killing, but giving IL-2 directly throughout the body causes serious toxicity because it activates immune and vascular cells indiscriminately. A bifunctional fusion protein that links a PD-1-binding component to an IL-2 component uses PD-1 as a docking site, directing IL-2 receptor stimulation preferentially toward the PD-1-expressing T cells found within tumors, rather than throughout the circulation. The intended result is a combined effect: checkpoint blockade releases the brake on these cells while localized IL-2 signaling pushes them to expand and differentiate into more effective killers, in principle achieving stronger antitumor activity with less systemic cytokine exposure than either approach alone. This mechanism is relevant across cancers characterized by T-cell exhaustion and limited local cytokine support.